Institut für Hämatopathologie Hamburg
☎ +49 (0) 40 707085-200 ✉ mrd@hp-hamburg.de

HPH MRD · Blood test in cancer follow-up

Detect residual cancer early with a simple blood sample.

HPH MRD detects tiny traces of remaining tumor DNA in blood and supports treatment decisions and follow-up care.

Laboratory work with HPH MRD sample
Sample transport for patients

For patients

What ctDNA is, how the test works, and answers to common questions.

Go to patient area

For medical professionals

Evidence, analytical sensitivity, sample logistics, and report examples.

Go to professional area
Lab analysis for medical professionals

In five steps

How it works

From test order to monitoring.

1

Test order

The physician orders the test.

2

Blood draw

The sample is taken in clinic or oncology practice.

3

Personalized test

Blood and tumor tissue are analyzed in the lab.

4

Result

The result is reported to the physician.

5

Monitoring

Follow-up visits may include another blood draw.

Who is the test for?

  • People with a confirmed cancer diagnosis
  • When surgery and/or systemic therapy is planned or completed
  • Not a screening test for healthy people

What the test does – and does not

HPH MRD provides additional disease information. It does not replace physician assessment, imaging, or standard follow-up. Interpretation and treatment decisions remain with the treating physician.